Market Cap 101.70M
Revenue (ttm) 0.00
Net Income (ttm) -71.27M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 336,800
Avg Vol 271,162
Day's Range N/A - N/A
Shares Out 15.02M
Stochastic %K 83%
Beta 2.69
Analysts Strong Sell
Price Target $53.88

Company Profile

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic sp...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 549 1400
Address:
2200 Bridge Pkwy, Suite 102, Redwood City, United States
DCRMIA
DCRMIA Jul. 7 at 12:19 PM
I'm gonna buy a bunch of $JSPR when the market opens🚀🚀🚀
0 · Reply
HITBC
HITBC Jul. 7 at 12:18 PM
$JSPR in here, oversold keeping $RGC till 35 and $TGE till 20 and $MLGO till double my money also $NCPL free money
0 · Reply
Messerschmittbf109
Messerschmittbf109 Jul. 7 at 12:18 PM
$JSPR On July 7, 2025, reported updated data from its BEACON Phase 1b/2a study of briquilimab in adult participants with chronic spontaneous urticaria. The study showed promising results, with 89% of participants in the 240mg and 360mg single-dose cohorts achieving a complete response. However, issues with a specific drug product lot affected results in some cohorts, leading to the halting of the ETESIAN study in asthma and a pause in development for SCID. Jasper plans to enroll additional patients to ensure robust data for future studies and is implementing cost-cutting measures to extend its financial runway. The most recent analyst rating on stock is a Buy with a $80.00 price target. To see the full list of analyst forecasts on Jasper Therapeutics stock, see the JSPR
0 · Reply
dogood
dogood Jul. 7 at 12:18 PM
0 · Reply
Dickbender
Dickbender Jul. 7 at 12:18 PM
$JSPR why is it down big .?
0 · Reply
AlgoSlayerPMPRO
AlgoSlayerPMPRO Jul. 7 at 12:17 PM
$JSPR This will close huge plus in green ⚡⚡⚡⚡⚡⚡⚡
0 · Reply
YouVSYou
YouVSYou Jul. 7 at 12:17 PM
$JSPR let’s see how this conference call goes I think this sees 4-5 again eventually worth cheap adds down here While it’s ugly
1 · Reply
SirAskCheeks
SirAskCheeks Jul. 7 at 12:16 PM
$JSPR lotto adds
0 · Reply
Sanjaynaik2011
Sanjaynaik2011 Jul. 7 at 12:16 PM
$JSPR This may double any time!!
0 · Reply
Bullshyte
Bullshyte Jul. 7 at 12:15 PM
$JSPR in my opinion, this is the opportunity of a life time...
1 · Reply
Latest News on JSPR
Jasper Therapeutics to Present at Upcoming Investor Conferences

May 14, 2025, 4:30 PM EDT - 7 weeks ago

Jasper Therapeutics to Present at Upcoming Investor Conferences


Jasper Therapeutics, Inc. Announces Reverse Stock Split

Jan 2, 2024, 8:00 AM EST - 1 year ago

Jasper Therapeutics, Inc. Announces Reverse Stock Split


DCRMIA
DCRMIA Jul. 7 at 12:19 PM
I'm gonna buy a bunch of $JSPR when the market opens🚀🚀🚀
0 · Reply
HITBC
HITBC Jul. 7 at 12:18 PM
$JSPR in here, oversold keeping $RGC till 35 and $TGE till 20 and $MLGO till double my money also $NCPL free money
0 · Reply
Messerschmittbf109
Messerschmittbf109 Jul. 7 at 12:18 PM
$JSPR On July 7, 2025, reported updated data from its BEACON Phase 1b/2a study of briquilimab in adult participants with chronic spontaneous urticaria. The study showed promising results, with 89% of participants in the 240mg and 360mg single-dose cohorts achieving a complete response. However, issues with a specific drug product lot affected results in some cohorts, leading to the halting of the ETESIAN study in asthma and a pause in development for SCID. Jasper plans to enroll additional patients to ensure robust data for future studies and is implementing cost-cutting measures to extend its financial runway. The most recent analyst rating on stock is a Buy with a $80.00 price target. To see the full list of analyst forecasts on Jasper Therapeutics stock, see the JSPR
0 · Reply
dogood
dogood Jul. 7 at 12:18 PM
0 · Reply
Dickbender
Dickbender Jul. 7 at 12:18 PM
$JSPR why is it down big .?
0 · Reply
AlgoSlayerPMPRO
AlgoSlayerPMPRO Jul. 7 at 12:17 PM
$JSPR This will close huge plus in green ⚡⚡⚡⚡⚡⚡⚡
0 · Reply
YouVSYou
YouVSYou Jul. 7 at 12:17 PM
$JSPR let’s see how this conference call goes I think this sees 4-5 again eventually worth cheap adds down here While it’s ugly
1 · Reply
SirAskCheeks
SirAskCheeks Jul. 7 at 12:16 PM
$JSPR lotto adds
0 · Reply
Sanjaynaik2011
Sanjaynaik2011 Jul. 7 at 12:16 PM
$JSPR This may double any time!!
0 · Reply
Bullshyte
Bullshyte Jul. 7 at 12:15 PM
$JSPR in my opinion, this is the opportunity of a life time...
1 · Reply
AlgoSlayerPMPRO
AlgoSlayerPMPRO Jul. 7 at 12:14 PM
$JSPR Positive News should bounce big, close im green & all the shorts covering as well ⚡⚡⚡⚡⚡
0 · Reply
UnoffensiveName
UnoffensiveName Jul. 7 at 12:13 PM
1 · Reply
dogood
dogood Jul. 7 at 12:11 PM
$JSPR should head back to $4
0 · Reply
Lamatozore
Lamatozore Jul. 7 at 12:06 PM
$JSPR omg 🧐
0 · Reply
Lamatozore
Lamatozore Jul. 7 at 12:06 PM
$JSPR wtf 🧐
0 · Reply
YouVSYou
YouVSYou Jul. 7 at 12:03 PM
$JSPR conference call should be interesting
0 · Reply
G101SPM
G101SPM Jul. 7 at 12:02 PM
$JSPR $1.88 bid. DAC (2) $1.835 [6.00] UPDATE 8 of 9 participants (89%) treated in the 240mg and 360mg single dose cohorts achieved a complete response 8 of 11 participants (73%) enrolled in the 180mg Q8W open label extension study achieved a complete response at 12 weeks Results from the 240mg Q8W and the 240mg followed by 180mg Q8W cohorts appear to be confounded by issues with one drug product lot ETESIAN study in asthma to be stopped due to same drug product lot issue No grade 3 or higher treatment related adverse events reported Company to host conference call and webinar today, Monday, July 7, at 8:30 a.m. EDT
0 · Reply
dogood
dogood Jul. 7 at 12:00 PM
$JSPR since all are covered take this to $5
0 · Reply
nUme22
nUme22 Jul. 7 at 11:59 AM
$JSPR now I can think of buying this .. maybe 30% from here..
0 · Reply
DCRMIA
DCRMIA Jul. 7 at 11:59 AM
0 · Reply
G101SPM
G101SPM Jul. 7 at 11:58 AM
$JSPR $1.75 ask. BUY/ADD TO LONG POSITION.
0 · Reply
Stmkr
Stmkr Jul. 7 at 11:58 AM
$JSPR Wow. Overreaction?
0 · Reply